COX-2 inhibition: a possible role in the management of prostate cancer? by Sooriakumaran, P, Langley, SE, Laing, R, Coley, H

A novel method of obtaining prostate tissue for gene expression profiling. by Sooriakumaran, P, Henderson, A, Denham, P, Langley, SE

Brachytherapy: the surgeon's perspective. by Henderson, A, Sooriakumaran, P, Laing, R, Langley, SE

Urinary morbidity after 125I brachytherapy of the prostate. by Henderson, A, Bott, SR, Sooriakumaran, P, Laing, R, Langley, SE

Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. by Nobes, J, Khaksar, S, Hawkins, M, Cunningham, M, Langley, SE, Laing, R

Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. by Nobes, J, Khaksar, S, Hawkins, M, Cunningham, M, Langley, SE, Laing, R

Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. by Khaksar, S, Laing, R, Henderson, A, Sooriakumaran, P, Lovell, D, Langley, SE

Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer. by Sooriakumaran, P, Lovell, D, Henderson, A, Denham, P, Langley, SE, Laing, R

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. by Sooriakumaran, P, Macanas-Pirard, P, Bucca, G, Henderson, A, Langley, SE, Laing, R, Smith, C, Laing, E, Coley, H

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. by Sooriakumaran, P, Coley, H, Fox, S, Macanas-Pirard, P, Lovell, D, Henderson, A, Eden, C, Miller, P, Langley, SE, Laing, R